Dr. Christophe Arbet-Engels talks about how the empagliflozin study results were very positive in terms of lowering A1c, and goes over the basics of how the new class of SGLT-2 inhibitor drugs work, removing excess glucose, inducing some weight loss, and that there is potential for a decrease in blood pressure …

Christophe Arbet-Engels, MD, PhD, MBA, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc., gives us a brief introduction to himself. Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources

Dr. Christophe Arbet-Engels, discusses some of the study results on empagliflozin in which more than 14,000 patients were involved in several different study configurations including monotherapy, empagliflozin as an add-on, and patients with renal impairment.   Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer …

Dr. Christophe Arbet-Engels explains how empagliflozin is being submitted to the FDA for treatment of diabetes indications and that there are different subgroups under this category. The FDA reviews the data and then may or may not grant approval or ask for more data. Christophe Arbet-Engels, MD, PhD, MBA, is vice …

Dr. Christophe Arbet-Engels discusses the clinical results of the empagliflozin studies focusing on the A1c drops which varied by study and were anywhere from .7 to 1% depending on the patient. He also differentiates between A1c drops due to weight loss and those due to the excretion of excess glucose which …

Dr. Christophe Arbet-Engels explains how empagliflozin could be dosed once approved. and that the highest dose showed the most benefit in trials with reductions in weight and blood pressure. Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources

Dr. Christophe Arbet-Engels continues his discussion of the potential for combining the SGLT-2 inhibitor empagliflozin with other drugs down the road, and that they will certainly be exploring these otpions.  Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources

Dr. Christophe Arbet-Engels explains that Boehringer Ingelheim will also be submitting empagliflozin internationally, and certainly in the EU, and that they will also look carefully at all possibilities to submit the drug to other international authorities. Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim …

Dr. Christophe Arbet-Engels answer the question, “Do the Swiss get diabetes?” and, on a more serious note, explains that they are exploring different options for different patient populations to find the best treatment possible for each individual patient.   Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, …

Dr. Christophe Arbet-Engels talks about some of the diabetes drugs in Boehringer Ingelheim’s pipeline including several compounds with liagliptin which BI is continuing to study and expand their knowledge of. They have looked at data in the past on African Americans and are now examining data of the drug’s efficacy in …